The cost effectiveness of transcatheter aortic valve implantation (TAVR) compared to surgical aortic valve replacement (SAVR) depends on whether TAVR is performed via the femoral artery or transapically, through a small incision in the chest, according to a new study.
Recently, transcatheter aortic valve implantation (TAVR) has been shown to result in similar 12-month survival as surgical aortic valve replacement (SAVR) for high-risk patients with severe aortic stenosis. The potential cost-effectiveness of TAVR versus SAVR in the PARTNER trial was examined and the results were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.
The PARTNER trial randomized patients with severe, symptomatic aortic stenosis and high surgical risk to either TAVR (N=348) or SAVR (N=351) and followed them for a minimum of 12 months. Health state utilities were estimated using the EuroQOL (EQ-5D) at baseline, one, six, and 12 months. Detailed medical resource utilization data were collected on all study patients, and hospital billing data were collected for both index and follow-up hospitalizations for any cause from consenting U.S. patients.
The objectives of the study were to combine cost data with survival and Quality of Life (QoL) data to estimate the12-month cost-effectiveness of TAVR compared with AVR and to explore potential differences in costs and cost-effectiveness of TAVR vs. AVR for the transfemoral vs. transapical populations.
Among high risk aortic stenosis patients eligible for the transfemoral approach, TAVR, compared with surgical AVR:Provided small but significant gains in 12 month quality-adjusted life expectancy (0.06 – 0.07 Quality Adjusted Life Years, QALYs)
Was associated with higher procedural costs but slightly lower index hospitalization and total 12 month costs
However, not all patients qualify medically for the transfemoral approach. Among patients only eligible for the transapical approach:TAVR provided no increase (and possible decrease) in QALYs
"Results of this trial indicate that for patients with severe aortic stenosis and high surgical risk, transcatheter aortic valve replacement is an economically attractive and possibly dominant strategy compared with surgical aortic valve replacement, provided that patients are suitable for the transfemoral approach," said Matthew R. Reynolds, MD. Dr. Reynolds is Director of the Economics and Quality of Life Research Center at Harvard Clinical Research Institute (HCRI), an Assistant Professor of Medicine at Harvard Medical School and Associate Director of Electrophysiology at the Boston VA Health Care System.
"Current results for transcatheter aortic valve replacement via the transapical approach, compared with surgical aortic valve replacement, are unattractive from a health economic perspective," said Dr. Reynolds.
"Whether the transapical approach can be refined to provide faster recovery and better results from a cost perspective should be the subject of further study."
The PARTNER trial is funded by a research grant from Edwards Lifesciences, Inc. Dr. Reynolds reported that his research organization (HCRI) receives research grant support from the company.
About CRF and TCT
The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies, drugs and therapies in interventional cardiovascular medicine.
Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of the Cardiovascular Research Foundation. TCT gathers leading medical researchers and clinicians from around the world to present and discuss the latest developments in the field.
Judy Romero | EurekAlert!
New bioimaging technique is fast and economical
21.08.2017 | Rensselaer Polytechnic Institute
Noninvasive eye scan could detect key signs of Alzheimer's years before patients show symptoms
18.08.2017 | Cedars-Sinai Medical Center
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
21.08.2017 | Materials Sciences
21.08.2017 | Health and Medicine
21.08.2017 | Materials Sciences